A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis - Study Results

A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis (PRIDE)

This study has been completed.

Study NCT00513370 Information provided by Abbott

First Received: August 6, 2007 Last Updated: October 13, 2009 History of Changes

Study Type:	Interventional
Study Design:	Non-Randomized, Open Label, Single Group Assignment
Condition:	Psoriasis
Intervention:	Biological: Humira (adalimumab)

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Adalimumab 40 mg Eow	adalimumab 40 mg every other week (eow)

Participant Flow: Overall Study

	Adalimumab 40 mg Eow
STARTED	203
COMPLETED	179
NOT COMPLETED	24

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Adalimumab 40 mg Eow	adalimumab 40 mg every other week (eow)

Baseline Measures

	Adalimumab 40 mg Eow
Number of Participants [units: participants]	203
Age [units: participants]
<=18 years	0
Between 18 and 65 years	192
>=65 years	11
Age [units: years] Mean ± Standard Deviation	45.5 ± 12.34
Gender [units: participants]
Female	79
Male	124
Region of Enrollment [units: participants]
Canada	203

Outcome Measures

Show All Outcome Measures

1. Primary:

Number of Subjects With Psoriasis Area and Severity Index (PASI) 75 Response at 16 Weeks [ 16 weeks ]

Show Outcome Measure 1

2. Secondary:

Mean Change and Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks [ 16 and 24 weeks ]

Show Outcome Measure 2

3. Secondary:

Number of Subjects With Improvement in Physician's Global Assessment for Psoriasis (PGA) [ 16 and 24 weeks ]

Show Outcome Measure 3

4. Secondary:

Number of Subjects Achieving a Clinical Response Defined as a Physician's Global Assessment for Psoriasis (PGA) of "Clear" or “Clear or Minimal” [ 16 and 24 weeks ]

Show Outcome Measure 4

5. Secondary:

Mean Change From Baseline in Physician Global Assessment of Arthritic Disease Activity [ 16 and 24 weeks ]

Show Outcome Measure 5

6. Secondary:

Number of Subjects With Psoriasis Area and Severity Index (PASI) 50/75/90/100 Response [ 16 and 24 weeks ]

Show Outcome Measure 6

7. Secondary:

Mean Change From Baseline in Tender Joint Count [ 16 and 24 weeks ]

Show Outcome Measure 7

8. Secondary:

Mean Change From Baseline in Swollen Joint Count [ 16 and 24 weeks ]

Show Outcome Measure 8

9. Secondary:

Mean Change From Baseline in Patient's Global Assessment of Joint Pain [ 16 and 24 weeks ]

Show Outcome Measure 9

10. Secondary:

Mean Change From Baseline in the Dermatology Life Quality Index (DLQI) [ 16 and 24 weeks ]

Show Outcome Measure 10

11. Secondary:

Number of Subjects Achieving a Dermatology Life Quality Index (DLQI) = 0 [ 16 and 24 weeks ]

Show Outcome Measure 11

12. Secondary:

Mean Change From Baseline in Beck Depression Inventory (BDI-II) [ 16 and 24 weeks ]

Show Outcome Measure 12

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: The first publication and presentation of this Study shall reside with Abbott. No independent manuscript may be submitted for publication until the first manuscript has been accepted for publication or twelve (12) months after completion of Study at all sites, which ever occurs first.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Medical Information Specialist
Organization: Abbott Laboratories
phone: 1-800-633-9110

No publications provided

Responsible Party:	Abbott ( Isabel Pereira, Affiliate Project Manager )
Study ID Numbers:	W10-151
Study First Received:	August 6, 2007
Results First Received:	August 21, 2009
Last Updated:	October 13, 2009
ClinicalTrials.gov Identifier:	NCT00513370 History of Changes
Health Authority:	Canada: Health Canada